ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-4681
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder? ; day:12 ; month:4 ; year:2022 ; pages:1-2
Annals of surgical oncology ; (12.4.2022), 1-2
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1245/s10434-022-11702-1
- URN
-
urn:nbn:de:101:1-2022062721321068631117
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mori, Keiichiro
- Schuettfort, Victor M.
- Egawa, Shin
- Compérat, Eva Maria
- Shariat, Shahrokh F.
- SpringerLink (Online service)
Other Objects (12)
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
Comparison between urothelial and non-urothelial urethral cancer
Focal therapy in intermediate- and high-risk prostate cancer
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
Comparison between urothelial and non-urothelial urethral cancer
Focal therapy in intermediate- and high-risk prostate cancer
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
Comparison between urothelial and non-urothelial urethral cancer
Focal therapy in intermediate- and high-risk prostate cancer
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis